Department of Cardiology, Centre of Internal Medicine III, Johann Wolfgang Goethe University Frankfurt am Main, Frankfurt, Germany.
Atherosclerosis. 2011 Dec;219(2):913-6. doi: 10.1016/j.atherosclerosis.2011.09.022. Epub 2011 Sep 21.
To investigate the possible association of plasma levels of stromal cell-derived factor-1 (SDF-1; CXCL12) with clinical presentation of symptomatic coronary artery disease (CAD) and with cardiovascular risk factors.
A cath lab cohort of 492 consecutive patients with symptomatic CAD were recruited. Blood for plasma-SDF-1 determination was taken at the time of heart catheterization before percutaneous coronary intervention.
Plasma-SDF-1 was significantly decreased in ST-elevation myocardial infarction (STEMI) compared to stable angina pectoris (SAP) or to non-ST-elevation myocardial infarction (NSTEMI) (SAP vs. NSTEMI vs. STEMI: [pg/ml]: mean ± SD: 2110 ± 562 vs. 2127 ± 467 vs. 1834 ± 377; P < 0.001) independent of cardiovascular therapy. A weak correlation was observed between cholesterol levels and plasma SDF-1 in the whole study population. Left ventricular function and diabetes mellitus associated with plasma SDF-1 levels in patients with NSTEMI, while among STEMI patients, those with hyperlipidemia presented with even further decreased SDF-1 levels.
Plasma SDF-1 is significantly decreased in patients with STEMI, a fact which may reflect the importance of SDF-1 regulation in patients with acute myocardial infarction.
探讨基质细胞衍生因子-1（SDF-1；CXCL12）的血浆水平与有症状的冠心病（CAD）的临床表现以及心血管危险因素的可能相关性。
在经皮冠状动脉介入治疗前的心脏导管插入术时采集了 492 例有症状 CAD 的连续患者的血液以用于测定血浆-SDF-1。
与稳定型心绞痛（SAP）或非 ST 段抬高型心肌梗死（NSTEMI）相比，ST 段抬高型心肌梗死（STEMI）患者的血浆-SDF-1 明显降低（SAP 比 NSTEMI 比 STEMI：[pg/ml]：均值±SD：2110±562 比 2127±467 比 1834±377；P＜0.001），与心血管治疗无关。在整个研究人群中观察到胆固醇水平与血浆 SDF-1 之间存在弱相关性。左心室功能和糖尿病与 NSTEMI 患者的血浆 SDF-1 水平相关，而在 STEMI 患者中，高脂血症患者的 SDF-1 水平甚至进一步降低。
STEMI 患者的血浆 SDF-1 明显降低，这一事实可能反映了 SDF-1 调节在急性心肌梗死患者中的重要性。
